Substance Details ADB-BUTINACA

AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narro

Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans
The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA and MDMB-4en-PINACA [39, 40]. Similar to the in-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models, consistent with the known hydrolytic activity of CES reported

4. Drugs
Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.
Michael B Gat


Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate in a dose-dependent manner. A total of 5 mice in the JWH-081 (5 mg/kg, i.p.) treated group and 6 mice in the 5CL ADBA powder JWH-210 (5 mg/kg, i.p.) treated group showed loss of traction, of which 4 and 5 showed tremor, respectively. Memory retention was measured after the memory acquisition was tested as a probe trial.
About Powder JWH-2


LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden 5CL ADBA powder headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl

The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human

Figure 1.
These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit


Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic


Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient.
Data availabili